Biodexa Pharmaceuticals Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Monitoring Framework
Key Performance Indicators
Phase 3 Serenta Trial Patient Enrollment Quarterly37.0
Cash and Cash Equivalents Quarterly8.5MTarget: Sufficient to fund operations beyond Q3 2026
Research and Development (R&D) Expenses Annually4MTarget: Optimized spend aligned with clinical milestones
Watch Items
- Cash Runway and Financing NeedsTrigger: Approaching Q3 2026 without securing additional non-dilutive or equity financingAction: Evaluate further drawdowns from the $35 million ELOC or seek strategic partnerships
- MTX240 Phase 1b/2a Trial InitiationTrigger: Failure to file IND and initiate the study by late 2026Action: Review manufacturing timelines with Syngene and optimize clinical trial design
- Nasdaq Listing ComplianceTrigger: Share price falling below $1.00 or failing to meet minimum market cap requirementsAction: Implement corporate restructuring or reverse stock splits to maintain listing
Research as of 20 Jun 2026